文献速递垂体与肾上腺疾病

靶向甲基化分析在石蜡包埋肾上腺皮质癌样本中的预后作用

Prognostic Role of Targeted Methylation Analysis in Paraffin-embedded Samples of Adrenocortical Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该研究纳入237例肾上腺皮质癌患者,从福尔马林固定石蜡包埋样本中提取肿瘤DNA,用靶向焦磷酸测序检测5个预选基因启动子区甲基化。PAX5高甲基化在多变量分析中仍与总生存显著相关(P=0.013;HR=1.95,95%CI 1.2-3.3),结合PAX5甲基化状态与S-GRAS分组的风险分层模型预后性能优于单用S-GRAS。

要点

  • PAX5、GSTP1、PYCARD、PAX6、G0S2高甲基化分别见于27.9%、13.9%、49%、49%、25.3%的病例。
  • 除GSTP1外,各基因高甲基化均与无进展生存和总生存显著相关,HR在1.4至2.3之间。
  • 多变量分析中仅PAX5高甲基化仍与总生存显著相关(P=0.013;HR=1.95,95%CI 1.2-3.3)。

核心结论

  • 本研究表明PAX5高甲基化与肾上腺皮质癌更差的临床结局相关,即使在考虑S-GRAS评分后仍如此。
  • 石蜡包埋材料甲基化评估在临床环境中简便易行,可用于提高预后分类准确性,从而指导个体化管理。

研究设计与样本

  • 研究纳入237例肾上腺皮质癌患者,从福尔马林固定石蜡包埋样本中提取肿瘤DNA。
  • 采用靶向焦磷酸测序检测5个预选基因(PAX5、GSTP1、PYCARD、PAX6、G0S2)启动子区甲基化。
  • 将高甲基化模式的预后作用与Stage、Grade、Resection status、Age、Symptoms(S-GRAS)评分进行比较。
  • 主要终点为无进展生存和总生存,无病生存为次要终点。

主要发现

  • PAX5、GSTP1、PYCARD、PAX6、G0S2高甲基化分别见于27.9%、13.9%、49%、49%、25.3%的病例。
  • 除GSTP1外,各基因高甲基化均与无进展生存和总生存显著相关,HR在1.4至2.3之间。
  • 多变量分析中仅PAX5高甲基化仍与总生存显著相关(P=0.013;HR=1.95,95%CI 1.2-3.3)。
  • 结合PAX5甲基化状态与S-GRAS分组的风险分层模型,其预后性能优于单用S-GRAS(Harrell's C指数:总生存=0.751,无进展生存=0.711,无病生存=0.688)。

关键数值与推荐

  • PAX5高甲基化多变量分析总生存:P=0.013;HR=1.95,95%CI 1.2-3.3。
  • 联合模型Harrell's C指数:总生存=0.751,无进展生存=0.711,无病生存=0.688。

临床怎么用

  • 石蜡包埋材料甲基化评估在临床环境中简便易行,可用于提高预后分类准确性,从而指导个体化管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adrenocortical carcinoma (ACC) is a rare aggressive disease with heterogeneous prognoses. Previous studies identified hypermethylation in the promoter region of specific genes to be associated with poor clinical outcome. OBJECTIVE: Comparative analysis of promising hypermethylated genes as prognostic markers and evaluation of their added value to established clinical prognostic tools. DESIGN: We included 237 patients with ACCs. Tumor DNA was isolated from formalin-fixed paraffin-embedded (FFPE) samples. Targeted pyrosequencing was used to detect promoter region methylation in 5 preselected genes (PAX5, GSTP1, PYCARD, PAX6, G0S2). The prognostic role of hypermethylation pattern was compared with the Stage, Grade, Resection status, Age, Symptoms (S-GRAS) score. Primary endpoints were progression-free (PFS) and overall survival (OS), with disease-free (DFS) as secondary endpoint. RESULTS: A total of 27.9%, 13.9%, 49%, 49%, and 25.3% of cases showed hypermethylation in PAX5, GSTP1, PYCARD, PAX6, and G0S2, respectively. Hypermethylation in all individual genes-except GSTP1-was significantly associated with both PFS and OS-with hazard ratios (HR) between 1.4 and 2.3. However, only hypermethylation of PAX5 remained significantly associated with OS (P = 0.013; HR = 1.95, 95% CI, 1.2-3.3) in multivariable analysis. A model for risk stratification was developed, combining PAX5 methylation status and S-GRAS groups, showing improved prognostic performance compared to S-GRAS alone (Harrell's C index: OS = 0.751, PFS = 0.711, DFS = 0.688). CONCLUSIONS: This study demonstrated that hypermethylation in PAX5 is associated with worst clinical outcome in ACC, even after accounting for S-GRAS score. Assessing methylation in FFPE material is straightforward in the clinical setting and could be used to improve accuracy of prognostic classification, enabling the direction of personalized management.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lippert J, Altieri B, Morrison B, et al. Prognostic Role of Targeted Methylation Analysis in Paraffin-embedded Samples of Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2022. PMID: 35929659. doi:10.1210/clinem/dgac470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。